Habib El‐Khoury

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population”.

Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population

Blood Advances(2024)10.1182/bloodadvances.2023010843

N/A

0.885DataRank · unranked

26 citations

Habib El‐Khoury, Angela C. Tramontano, Jean-Baptiste Alberge, Jacqueline Perry, Maya Davis +11 more

Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors

Cancer Cell(2022)10.1016/j.ccell.2022.08.022

N/A

0.717DataRank · unranked

118 citations

Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha, Elie W. Akl +27 more

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

medRxiv(2024)10.1101/2024.04.19.24306082

N/A

0.343DataRank · unranked

6 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study

The Lancet Haematology(2023)10.1016/s2352-3026(22)00386-6

N/A

0DataRank · unranked

81 citations

Federico Ferrari, Samuel S. Freeman, Robert Redd, Habib El‐Khoury, Jacqueline Perry +29 more

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

Nature Communications(2025)10.1038/s41467-024-55308-5

N/A

0DataRank · unranked

14 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more